Rivermark Medical, a leader in minimally invasive solutions for Benign Prostatic Hyperplasia (BPH), closed a $30 million Series C financing round. The round was led by American Century Investments (ACI) including new investors Venture Investors Health Fund, Time BioVentures, and an unnamed strategic investor, with follow-on participation from existing investors View Ventures, Cadence Healthcare Ventures, and Anduril Investors LLC.
Related: Siloton secures £860k to advance eye imaging chip for AMD
Funds will advance the clinical development of Rivermark’s flagship product, the FloStent™ System, designed to restore urinary function for BPH patients. The device, currently in clinical development, offers a minimally invasive approach with quick recovery times, reversibility, and suitability for outpatient procedures.
“We’re grateful for the support of our investors as we progress toward bringing the FloStent System to market,” said Adam Kadlec, President and CEO of Rivermark Medical. “This financing will accelerate our clinical programs and our path to commercialization, providing a new solution for the millions affected by BPH.”
BPH is a non-cancerous condition caused by an enlarged prostate, impacting the quality of life in approximately 1 in 3 men over the age of 50. It can lead to uncomfortable symptoms such as frequent urination, difficulty urinating, and urinary tract infections (UTIs). Rivermark’s FloStent System is a uniquely engineered nitinol stent that gently holds the prostatic urethra open to restore normal urinary flow while preserving sexual function. The device is designed for rapid patient relief with minimal discomfort and can be deployed minimally invasively during an outpatient visit, offering fewer complications and minimal recovery time.
“We believe Rivermark is poised to make a transformative impact on BPH treatment with their innovative FloStent System,” added Joe Biller, Managing Partner at American Century Investments. “Existing therapies provide challenges for patients including a difficult recovery process, diminished sexual function, and irreversibility. We’re excited to support a technology that is uniquely engineered to address meaningful unmet needs.”
